Tucatinib (Tukysa) is used in the treatment of more advanced or metastatic HER2+ breast cancer or HER2+ colorectal cancer, while Neratinib (Nerlynx) is used in the treatment of both early-stage and advanced or metastatic HER2+ breast cancer, but is not approved for use in colorectal cancer.